Insulet Co. (NASDAQ:PODD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Insulet Co. (NASDAQ:PODD) has earned a consensus rating of “Moderate Buy” from the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $243.21.

Several analysts have commented on PODD shares. Stifel Nicolaus lifted their price objective on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Barclays decreased their target price on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. JPMorgan Chase & Co. increased their price target on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, Piper Sandler decreased their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd.

Insider Buying and Selling

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares of the company’s stock, valued at $418,215.64. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Insulet

A number of large investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust raised its position in shares of Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 123 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 92 shares during the last quarter. Sunbelt Securities Inc. acquired a new position in shares of Insulet during the first quarter valued at approximately $29,000. Wolff Wiese Magana LLC lifted its position in shares of Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 134 shares in the last quarter. Finally, BluePath Capital Management LLC acquired a new stake in shares of Insulet in the third quarter worth approximately $31,000.

Insulet Stock Performance

Shares of PODD stock opened at $166.25 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. The business has a fifty day moving average of $173.97 and a 200 day moving average of $178.81. The firm has a market capitalization of $11.64 billion, a price-to-earnings ratio of 57.13, a price-to-earnings-growth ratio of 2.99 and a beta of 0.98. Insulet has a 1 year low of $125.82 and a 1 year high of $335.91.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.73. The firm had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The company’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period last year, the business posted $0.55 earnings per share. As a group, research analysts expect that Insulet will post 3.08 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.